Navigation Links
Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Date:2/11/2008

the commercial introduction of

Zingo.

Adlea

-- Continued enrollment in two Phase 2 trials of Adlea for post-operative

pain associated with orthopedic surgeries: one in patients undergoing

total hip replacement surgery, and a second in patients undergoing knee

replacement surgery. These trials are investigating a higher dose of

Adlea that might provide increased efficacy. Anesiva previously

successfully studied a lower dose of Adlea in patients undergoing knee

replacement surgery.

-- Proceeded with plans to initiate Phase 3 trials of Adlea in

post-surgical pain associated with orthopedic surgeries, including one

trial in patients undergoing bunionectomy surgeries and one trial in

patients undergoing total knee replacement surgeries.

Corporate Developments

Anesiva announced that Richard P. Powers, vice president and chief financial officer, will resign at the end of the month to pursue other interests, while remaining a consultant to the company. He will be succeeded by Jean-Frederic Viret, Ph.D., who is currently Anesiva's vice president, finance.

"Dick has been a valuable member of the Anesiva senior management team, having served as chief financial officer and leader of successful financing efforts almost since the company's inception. We are grateful for his many contributions and will appreciate the ongoing benefit of his counsel," said Mr. McLaughlin. "We are also pleased that we will have a smooth transition with the promotion of Jean Viret to vice president and chief financial officer. Jean has been a leader in our finance group since 2002, and we are confident that in this new position he will have a significant role in Anesiva's growth."

Jean-Frederic Viret, Ph.D. joined Anesiva in 2002 and was promoted to vice president, finance in 2006. Prior to Anesiva, Jean was associate director of finance at Tularik Inc. (now Amg
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Anesiva Appoints Daniel Janney to Board of Directors
2. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
3. Anesiva Announces Completion of Common Stock Offering
4. Anesiva Raises $45 Million in Common Stock Offering
5. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
6. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Narcotic and Pain-Management Market ... ... American Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading marketer, ... China,Aoxing Pharmaceutical Company, Inc. (OTC Bulletin Board: CAXG) ("China,Aoxing"), a ...
... CryoPort, Inc. (OTC,Bulletin Board: CYRX) (http://www.CryoPort.com ... personal profile on MyWallst.net available at, http://www.wallst.net . ... on which investors can comment, and links to ... Mywallst.net at, http://my.wallst.net/profile.php?ID=19849 . Stay updated about ...
... In Vivo ... Imaging-, HOPKINTON, ... introduced Bioware(R) Ultra cell lines,a range of ultra bright light producing tumor ... are,10 to 100 times brighter than cell lines created using traditional methods,which ...
Cached Biology Technology:American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 2American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 3American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 4CryoPort Creates Personal Wall on Wallst.net's Financial Social Community, my.wallst.net 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... 2009) Brief but personal intervention reduces drinking among ... The University of Texas School of Public Health. Results ... issue of the Journal of Consulting and Clinical ... UT School of Public Health Dallas Regional Campus, led ...
... Jan. 30, 2009 Screening a chemical library of ... identified two new classes that can be used to ... many types of cancer and degenerative diseases. "The ... cellular pathway represents an important step in developing therapeutic ...
... An experiment to study the effects of naturally deposited ... key piece of the puzzle surrounding iron,s role in ... research, conducted by an international team led by Raymond ... Matthew Charette, a marine chemist at the Woods Hole ...
Cached Biology News:Intervention method reduces binge drinking 2UT Southwestern researchers disrupt biochemical system involved in cancer, degenerative disease 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 3
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
1 unit is sufficient for 1 caspase activity assay....
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: